{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:28:17Z","timestamp":1774686497211,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT00435045"],"award-info":[{"award-number":["NCT00435045"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.4065\/mcp.2009.0397","type":"journal-article","created":{"date-parts":[[2010,1,29]],"date-time":"2010-01-29T19:04:28Z","timestamp":1264791868000},"page":"122-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Effects of Prescription Omega-3-Acid Ethyl Esters on Non\u2014High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin"],"prefix":"10.4065","volume":"85","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph T.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick N.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/mcp.2009.0397_bib1","first-page":"S1152","article-title":"Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin in patients with hypertriglyceridemia [abstract 5150]","volume":"118","author":"Bays","year":"2008","journal-title":"Circulation"},{"key":"10.4065\/mcp.2009.0397_bib2","unstructured":"Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Prescription omega-3s coadministered with atorvastatin for patients with hypertriglyceridemia. Encore poster presented at: American Association of Diabetes Educators 2009 Annual Meeting; August 5-8, 2009, Atlanta, GA."},{"key":"10.4065\/mcp.2009.0397_bib3","unstructured":"Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin on non-HDL-C in patients with hypertriglyceridemia. Encore poster presented at: American College of Clinical Pharmacy Annual Meeting 2009, Anaheim, CA, October 18-21, 2009."},{"issue":"25","key":"10.4065\/mcp.2009.0397_bib4","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"issue":"15","key":"10.4065\/mcp.2009.0397_bib5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation","volume":"51","author":"Brunzell","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.4065\/mcp.2009.0397_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"10.4065\/mcp.2009.0397_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/Tex-CAPS)","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"issue":"23","key":"10.4065\/mcp.2009.0397_bib8","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.4065\/mcp.2009.0397_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/mcp.2009.0397_bib10","series-title":"Your Guide to Lowering Cholesterol With TLC: Therapeutic Lifestyle Changes","author":"U. S. Department of Health and Human Services","year":"2005"},{"issue":"4","key":"10.4065\/mcp.2009.0397_bib11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.4065\/mcp.2009.0397_bib12","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"issue":"2","key":"10.4065\/mcp.2009.0397_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2796.1998.00297.x","article-title":"Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia","volume":"243","author":"Nord\u00f8y","year":"1998","journal-title":"J Intern Med"},{"issue":"5","key":"10.4065\/mcp.2009.0397_bib14","first-page":"544","article-title":"An omega-3 polyun-saturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia","volume":"85","author":"Durrington","year":"2001","journal-title":"Heart"},{"issue":"1","key":"10.4065\/mcp.2009.0397_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ajcn\/84.1.37","article-title":"Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity","volume":"84","author":"Chan","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.4065\/mcp.2009.0397_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.amjcard.2008.03.078","article-title":"Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg\/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia [published correction appears in am J Cardiol. 2008;102(10):1425]","volume":"102","author":"Maki","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2009.0397_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MOL.0b013e328321b3be","article-title":"Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes","volume":"20","author":"Hartweg","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.4065\/mcp.2009.0397_bib18","author":"Balk","year":"2004"},{"issue":"3","key":"10.4065\/mcp.2009.0397_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4A","key":"10.4065\/mcp.2009.0397_bib20","doi-asserted-by":"crossref","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/mcp.2009.0397_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0022-2275(20)30473-9","article-title":"Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype","volume":"43","author":"Khan","year":"2002","journal-title":"J Lipid Res"},{"issue":"5","key":"10.4065\/mcp.2009.0397_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.4065\/mcp.2009.0397_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.mol.0000236363.63840.16","article-title":"Why do omega-3 fatty acids lower serum triglycerides?","volume":"17","author":"Harris","year":"2006","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.4065\/mcp.2009.0397_bib24","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1194\/jlr.M600273-JLR200","article-title":"Trans geometric isomers of EPA decrease LXR\u03b1-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1\u03b2","volume":"47","author":"Zaima","year":"2006","journal-title":"J Lipid Res"},{"issue":"8A","key":"10.4065\/mcp.2009.0397_bib25","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data\u20132005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2009.0397_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/clc.4960260105","article-title":"Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia","volume":"26","author":"Isaacsohn","year":"2003","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.4065\/mcp.2009.0397_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1358\/dot.2008.44.3.1166387","article-title":"Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians","volume":"44","author":"Bays","year":"2008","journal-title":"Drugs Today (Barc)"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:41:33Z","timestamp":1706002893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611603844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0025619611603844"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2009.0397","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Prescription Omega-3-Acid Ethyl Esters on Non\u2014High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2009.0397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}